NT_1170x120_1-11-18

Janssen pharmaceutical

Johnson & Johnson to buy Actelion for $30 billion

Johnson & Johnson to buy Actelion for $30 billion

NEW BRUNSWICK, N.J. — Johnson & Johnson has reached an agreement to acquire Switzerland-based biopharmaceutical company Actelion Ltd. for $30 billion in cash. J&J said Actelion’s differentiated, innovative products for pulmonary arterial hypertension (PAH) are highly complementary to the portfolio of the Janssen Pharmaceutical Companies of Johnson & Johnson. The company also noted that the

J&J, P&G collaborations target flu, heart disease

J&J, P&G collaborations target flu, heart disease

Two major drug chain manufacturer partners — Johnson & Johnson and Procter & Gamble — are involved in collaborations that could make a big impact in fighting flu and heart disease. Scientists from The Scripps Research Institute (TSRI) and J&J’s Janssen pharmaceutical subsidiary have found a way to induce antibodies to fight a wide range